Capital Analysts LLC’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Capital Analysts LLC’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,057	Closed	-$84K	–	1138
2022 Q2	$84K	Buy	1,057 +271	+34%	+$25.7K	0.01%	457
2022 Q1	$83K	Hold	786	–	–	0.01%	464
2021 Q4	$85K	Hold	786	–	–	0.01%	478
2021 Q3	$86K	Buy	786 +212	+37%	+$22K	0.01%	485
2021 Q2	$54K	Buy	+574	New	+$52.8K	﹤0.01%	550
2020 Q4	–	Sell	-19,550	Closed	-$1.52M	–	838
2020 Q3	$1.52M	Buy	19,550 +4,650	+31%	+$320K	0.14%	126
2020 Q2	$828K	Buy	14,900 +7,900	+113%	+$338K	0.09%	161
2020 Q1	$207K	Sell	7,000 -3,250	-32%	-$110K	0.03%	205
2019 Q4	$371K	Buy	10,250 +4,750	+86%	+$146K	0.04%	197
2019 Q3	$149K	Buy	+5,500	New	+$142K	0.02%	243

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Capital Analysts LLC's HZNP Position: Q3 2022 in Review

Capital Analysts LLC sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022, closing a stake of 1,057 shares — an estimated $84K sold.

Capital Analysts LLC first reported a position in HZNP in Q3 2019 and held it in 10 quarters. The position peaked at $1.52M in Q3 2020. 530 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

Capital Analysts LLC reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2022 after selling out during the quarter.
Capital Analysts LLC sold 1,057 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $84K.
Capital Analysts LLC first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2019 and held it in 10 quarters.
Capital Analysts LLC's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.52M in Q3 2020.
530 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on Capital Analysts LLC's 13F filing for Q3 2022, filed 14 Nov 2022.